Literature DB >> 3196003

Efficacy of NY-198 against experimental Legionnaires disease.

S Kohno1, K Yamaguchi, Y Dohtsu, H Koga, T Hayashi, M Hirota, A Saito, K Hara.   

Abstract

The in vitro and in vivo effects of NY-198 against Legionella pneumophila were compared with those of ciprofloxacin. The MIC of NY-198 against 15 standard reference strains of Legionella of various species, between 0.03 and 0.125 micrograms/ml, was the same as that of ciprofloxacin. The peak concentration of NY-198 in the lungs and sera of guinea pigs with experimentally induced Legionella pneumonia was higher than that of ciprofloxacin after oral administration. The overall survival rate was higher in animals treated with NY-198 than in those treated with ciprofloxacin. Thus, NY-198 appears valuable in the treatment of Legionnaires disease.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3196003      PMCID： PMC175881          DOI： 10.1128/AAC.32.9.1427

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  [The first case of Legionnaires' disease in Japan (author's transl)].

Authors:  A Saito; T Shimoda; M Nagasawa; H Tanaka; N Ito; Y Shigeno; K Yamaguchi; M Hirota; M Nakatomi; K Hara
Journal:  Kansenshogaku Zasshi       Date:  1981-02

3.  Antimicrobial resistance of Neisseria gonorrhoea in Bangkok: is single-drug treatment passé.

Authors:  S Brown; T Warnnissorn; J Biddle; K Panikabutra; A Traisupa
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

4.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs.

Authors:  A Saito; K Sawatari; Y Fukuda; M Nagasawa; H Koga; A Tomonaga; H Nakazato; K Fujita; Y Shigeno; Y Suzuyama
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Studies on ciprofloxacin therapy of experimental Legionnaires' disease.

Authors:  R B Fitzgeorge; D H Gibson; R Jepras; A Baskerville
Journal:  J Infect       Date:  1985-05       Impact factor: 6.072

7.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes.

Authors:  H Koga
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

9.  Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs.

Authors:  P H Edelstein; K Calarco; V K Yasui
Journal:  Am Rev Respir Dis       Date:  1984-11

10.  Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis.

Authors:  E Dournon; P Rajagopalan; J L Vilde; J J Pocidalo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790
View more
  5 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes.

Authors:  K Taira; H Koga; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 5.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.